Press releases

Functional human intestine grown from stem cells

Press release | 21 Nov 2016 - 18h53 | By INSERM PRESS OFFICE
Circulation, metabolism, nutrition

photo-mahe

Cross-section of human intestinal organoid with enteric nervous system after transplantation in mice.*

(Copyright CCHMC – Wells/Helmrath labs)

American researchers at the Cincinnati Children’s Hospital Medical Center and French researchers from Inserm (joint research Unit 913 “Neuropathies of Enteric Nervous System and Digestive Diseases”, Nantes) have succeeded in generating a functional human intestine using pluripotent human stem cells. This significant breakthrough was achieved by cultivating human intestinal tissue using nerve cells. Details of their work are published online on 21 November 2016 in Nature Medicine.

 

The gut is an essential organ of the human body. It is the main interface for exchanges with the external environment and has a surface area equivalent to two tennis courts. Given its importance, the gut has its own nervous system and has been commonly known as “the second brain”. The enteric nervous system controls many functions, which include mixing and propelling food along the digestive tract, hormone secretion and epithelial permeability. Disruptions of this system are the cause of many diseases. Poor gut function can actually affect intestinal muscle contraction. This plays a role in triggering abdominal pain, diarrhoea, constipation and, in serious cases, leads to functional obstruction (intestinal occlusion) that requires surgery.

Researchers have developed an innovative approach to engineering tissue involving the use of stem cells to create a functional human intestine that can be used to study intestinal diseases.

First in vitro studies — finding the right balance

To do this, the scientists successively added a cocktail of molecules designed to promote the differentiation of human pluripotent stem cells into intestinal tissue. The process was virtually the same used in 2010 and 2014 by the same laboratory that succeeded in developing the first generation of human intestinal tissue. However, the intestinal tissue did not possess an enteric nervous system through this approach alone, which is essential for absorbing nutrients and eliminating waste through the digestive tract.

At the same time and in order to develop a functional nervous system, researchers created embryonic nerve cells known as neural crest cells. These cells were manipulated to form cells that are enteric neural cell precursors. “The difficulty with this step was to identify how and when to incorporate the neural crest cells into the developing gut that was previously created in vitro”, explains Maxime Mahé, first co-author of this work and recently recruited as a junior research associate by Inserm.

The co-culture of intestinal tissue and enteric neural cell precursors resulted in human tissue that resembled a developing fetal intestine. This led to the first generation of complex and functional “mini-intestines” (known as intestinal organoids) created entirely from human pluripotent stem cells.

 

Conclusive in vivo trials

The next challenge was to transplant these functional organoids into a living organism, in this instance, lab mice that lacked an immune system. This step allowed scientists to observe tissue development and function in vivo. Data from this study show that the tissues function and are structured in a way that is remarkably similar to the human intestine. They develop and ensure intestinal functions, such as the treatment of nutrients. Finally, these tissues exhibit motor functions similar to peristalsis, i.e. the series of muscle contractions that move food through the digestive tract.

Researchers then used this technology to study a rare bowel disease — Hirschsprung Disease — a disorder where the rectum and colon do not develop a nervous system, which leads to constipation and intestinal occlusion. A lethal form of Hirschsprung disease is caused by a mutation of the PHOX2B gene. In vitro tests in mice have made it possible for researchers to show that the mutated PHOX2B gene causes significant deleterious changes in the innervated intestinal tissues.

“Our work marks an essential step in understanding human digestive diseases where few models exist. This new technology offers a screening platform for new intestinal treatments. This technology is still in its infancy. However, an approach towards regenerative and personalised medicine is possible, particularly with regards to patient-specific intestinal transplantation”, explains Maxime Mahé.

This discovery yields two significant research possibilities. Firstly, intestinal disorders can be modelled and studied using three-dimensional and functional human tissue involving patient-specific cells. Secondly, new treatments can be tested using this functional human intestine before proposing clinical trials in humans.

 

In this image we can see the intestinal epithelium in red (E-cadherin) with lumen opening. The tissue underlying the epithelium is rich in blood vessels (green, CD31) and has neurons (yellow, TUBB3) that are also derived from human pluripotent stem cells. The observed tissue is incredibly similar to normal human tissue.

TO CITE THIS POST :
Press release – Inserm press room Functional human intestine grown from stem cells Link : http://presse.inserm.fr/en/functional-human-intestine-grown-from-stem-cells/25781/
Medias
Researcher Contact

Maxime Mahe

Instructor Cincinnati Children’s Hospital

Recently recruited as a junior research associate by Inserm, Inserm 913 Unit « Neuropathies of enteric nervous system and digestives diseases », Nantes

Tel:  513 602-6899

Mel: maxime.mahe@cchmc.org

 

Michel Neunlist

Research Director, Inserm

Head of Inserm 913 Unit « Neuropathies of enteric nervous system and digestives diseases », Nantes

Tel : +33 2 40 41 28 44

Mel : michel.neunlist@univ-nantes.fr

Press Contact

presse@inserm.fr

Sources

“Engineered human pluripotent stem cell-derived intestinal tissues with a functional enteric nervous system”

Michael J. Workman1#, Maxime M. Mahe2#, Stephen Trisno1, Holly M. Poling2 Carey L. Watson2, Nambirajan Sundaram2, Ching-Fang Chang1,3, Jacqueline Schiesser1, Philippe Aubert4, Edouard G. Stanley5,6,7, Andrew G. Elefanty5,6,7, Yuichir Miyaoka8,  Mohammad A. Mandegar8, Bruce R. Conklin8,9, Michel Neunlist4, Samantha A.Brugmann1,3, Michael A. Helmrath*2, and James M. Wells*1,10.

1 Division of Developmental Biology,

2 Division of Pediatric General and Thoracic Surgery,

3 Division of Plastic Surgery,

4 INSERM UMR 913, University of Nantes, CHU de Nantes – Institut des Maladies de l’Appareil Digestif, 1 Rue Gaston Veil, 44035 Nantes, France,

5 Murdoch Children’s Research Institute, The Royal Children’s Hospital,Flemington Rd, Parkville, Victoria 3052, Australia,

6 Department of Pediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria 3052, Australia,

7 Faculty of Medicine, Nursing and Health Sciences, Monash University,Clayton, Victoria 3800, Australia,

8 Gladstone Institutes, San Francisco CA, 94158, USA,

9 Departments of Medicine and Molecular and Cellular Pharmacology, University of California San Francisco, San Francisco CA, USA,

10 Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA.

Nature medicine

http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4233.html

fermer
fermer
RSS Youtube